Scholarlink

<p>Clinical trial experience supports the use of myosin inhibitors in hypertrophic cardiomyopathy (HCM), while early proof-of-concept studies suggest potential benefit in selected patients with heart failure with preserved ejection fraction (HFpEF). However, concerns about systolic dysfunction arising from their negative inotropic effects may limit broader application. In a series of in vivo and in vitro experiments in healthy animal preparations, we investigated how aficamten, a next-generation cardiac myosin inhibitor, interacts with key determinants of myocardial contractile function. Echocardiographic examinations in sedated Wistar rats revealed that bolus administration of aficamten (2&#xa0;mg·kg<sup>−1</sup> i.v.) did not reduce cardiac output (CO) at pacing frequencies of 300 and 400&#xa0;bpm, despite marked increases in end-diastolic (ED) and end-systolic left ventricular (LV) volumes and the associated decrease in LV ejection fraction (EF). In field-stimulated intact cardiomyocytes from Mongrel dogs, increasing aficamten concentrations (0.1–1&#xa0;µM) decreased contraction amplitude and diastolic duration. These effects occurred across pacing frequencies (0.25–1.25&#xa0;Hz) and in the absence of aficamten-specific changes in intracellular Ca<sup>2+</sup> transients. In permeabilized LV cardiomyocytes from dog and rat hearts, aficamten decreased active force production (F<sub>max</sub>) and its Ca<sup>2+</sup> sensitivity under isometric conditions in a similar manner. Importantly, the sarcomere length dependence of F<sub>max</sub> was preserved, while the length-dependent increase in Ca<sup>2+</sup> sensitivity was attenuated at higher (0.1–0.2&#xa0;µM) aficamten concentrations in both species. Our findings in healthy myocardium characterize aficamten as a myosin inhibitor that increases diastolic chamber volumes through reduced contractility, with diastolic function indices (i.e. E/e', IVRT) reflecting the expected hemodynamic consequences of increased preload rather than direct impairment of myofibrillar relaxation. This enhanced preload recruits preserved sarcomere length-dependent force generation to compensate for negative inotropy, thereby maintaining stroke volume and cardiac output.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Myofilament-level effects of aficamten increase diastolic chamber volumes and maintain cardiac output through preserved length-dependent force generation in healthy rat and canine myocardium

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月26日

查看全文
  • Fruzsina Sárkány,
  • Dániel Priksz,
  • Béla Juhász,
  • László Ádám Fazekas,
  • Norbert Németh,
  • Norbert Szentandrássy,
  • Balázs Horváth,
  • Zsigmond Máté Kovács,
  • Attila Borbély,
  • Arnold Péter Ráduly,
  • Attila Tóth,
  • Miklós Fagyas,
  • Beáta Bódi,
  • Zoltán Papp

摘要

Clinical trial experience supports the use of myosin inhibitors in hypertrophic cardiomyopathy (HCM), while early proof-of-concept studies suggest potential benefit in selected patients with heart failure with preserved ejection fraction (HFpEF). However, concerns about systolic dysfunction arising from their negative inotropic effects may limit broader application. In a series of in vivo and in vitro experiments in healthy animal preparations, we investigated how aficamten, a next-generation cardiac myosin inhibitor, interacts with key determinants of myocardial contractile function. Echocardiographic examinations in sedated Wistar rats revealed that bolus administration of aficamten (2 mg·kg−1 i.v.) did not reduce cardiac output (CO) at pacing frequencies of 300 and 400 bpm, despite marked increases in end-diastolic (ED) and end-systolic left ventricular (LV) volumes and the associated decrease in LV ejection fraction (EF). In field-stimulated intact cardiomyocytes from Mongrel dogs, increasing aficamten concentrations (0.1–1 µM) decreased contraction amplitude and diastolic duration. These effects occurred across pacing frequencies (0.25–1.25 Hz) and in the absence of aficamten-specific changes in intracellular Ca2+ transients. In permeabilized LV cardiomyocytes from dog and rat hearts, aficamten decreased active force production (Fmax) and its Ca2+ sensitivity under isometric conditions in a similar manner. Importantly, the sarcomere length dependence of Fmax was preserved, while the length-dependent increase in Ca2+ sensitivity was attenuated at higher (0.1–0.2 µM) aficamten concentrations in both species. Our findings in healthy myocardium characterize aficamten as a myosin inhibitor that increases diastolic chamber volumes through reduced contractility, with diastolic function indices (i.e. E/e', IVRT) reflecting the expected hemodynamic consequences of increased preload rather than direct impairment of myofibrillar relaxation. This enhanced preload recruits preserved sarcomere length-dependent force generation to compensate for negative inotropy, thereby maintaining stroke volume and cardiac output.